Sign in Subscribe
Financial markets

DBV Technologies to Participate in ACAAI 2025 Annual Scientific Meeting

Strategic Insights

— 2 min read

DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The Company will host a Product Theater titled "Harnessing Immune Plasticity to Alter the Path of Food Allergy," featuring a panel of renowned allergists discussing immunological and clinical evidence in support of earlier intervention in food allergy management. A Phase 2 clinical study assessing the efficacy and safety of the VIASKIN(R) Peanut patch will be presented, aiming to achieve ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age following a minimum of 3 years of treatment.

Key Takeaways:

  • DBV Technologies will participate in the ACAAI 2025 Annual Scientific Meeting, hosting a Product Theater titled "Harnessing Immune Plasticity to Alter the Path of Food Allergy."
  • The panel discussion will feature Drs. Gideon Lack, Hugh Sampson, George du Toit, Kirsten Perrett, and Matthew Greenhawt, exploring immunological and clinical evidence supporting earlier intervention in food allergy management.
  • A Phase 2 clinical study will assess the efficacy and safety of the VIASKIN(R) Peanut patch in achieving ad lib consumption of dietary peanut in peanut-allergic infants 6 through 12 months of age.
  • DBV's emphasis on proactive approaches to food allergy management reflects a growing shift in the field, with a focus on early introduction of potential allergens and immunomodulatory interventions.
  • The Company's presentation on the end-of-study results from the EPOPEX study highlights the long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers.
  • DBV Technologies is committed to transforming the care of food allergic individuals, with ongoing clinical trials examining the VIASKIN(R) Peanut patch in toddler and child populations.
  • The Company will exhibit at booth #711 and sponsor the 34th Annual FIT Bowl(TM), a game show-type competition testing allergy, asthma, and immunology knowledge among participating teams.

Statistics:

  • 34th Annual FIT Bowl will be held on Saturday, November 8th, from 5:45 p.m. to 7:45 p.m. ET.
  • VIASKIN(R) Peanut patch aims to assess efficacy and safety in achieving ad lib consumption in peanut-allergic infants 6 through 12 months of age.
  • End-of-study results from the EPOPEX study demonstrate long-term efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers.
  • DBV's participation in ACAAI 2025 highlights the Company's commitment to advancing food allergy research and treatment options.
  • VIASKIN(R) Peanut patch has shown promising results in earlier clinical trials, with DBV aiming to submit a BLA to the FDA in the second half of 2026.

Sources:

  • GLOBE NEWSWIRE via COMTEX) -- Chatillon, France, October 30, 2025
  • DBV Technologies press release announcing participation in ACAAI 2025 Annual Scientific Meeting.
  • SEC filings and reports by DBV Technologies, including its Annual Report on Form 10-K for the year ended December 31, 2024.

Read more